vs

Side-by-side financial comparison of AMERICOLD REALTY TRUST (COLD) and Moderna (MRNA). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $577.9M, roughly 1.8× AMERICOLD REALTY TRUST). AMERICOLD REALTY TRUST runs the higher net margin — -2.4% vs -19.7%, a 17.3% gap on every dollar of revenue. On growth, AMERICOLD REALTY TRUST posted the faster year-over-year revenue change (-1.2% vs -45.4%). Over the past eight quarters, AMERICOLD REALTY TRUST's revenue compounded faster (-5.4% CAGR vs -45.0%).

Americold Realty Trust, Inc. is an American temperature controlled warehousing and transportation company based in Atlanta, Georgia, United States. It is in the business of modern commercialized temperature controlled warehousing for the storage of perishable goods via a cold chain, one of the forms of food preservation. Americold is the 2nd largest temperature-controlled warehousing and distribution services provider in the world.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

COLD vs MRNA — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.8× larger
MRNA
$1.0B
$577.9M
COLD
Growing faster (revenue YoY)
COLD
COLD
+44.2% gap
COLD
-1.2%
-45.4%
MRNA
Higher net margin
COLD
COLD
17.3% more per $
COLD
-2.4%
-19.7%
MRNA
Faster 2-yr revenue CAGR
COLD
COLD
Annualised
COLD
-5.4%
-45.0%
MRNA

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
COLD
COLD
MRNA
MRNA
Revenue
$577.9M
$1.0B
Net Profit
$-13.7M
$-200.0M
Gross Margin
79.6%
Operating Margin
2.5%
-25.6%
Net Margin
-2.4%
-19.7%
Revenue YoY
-1.2%
-45.4%
Net Profit YoY
16.9%
-1638.5%
EPS (diluted)
$-0.05
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COLD
COLD
MRNA
MRNA
Q1 26
$577.9M
Q4 25
$643.1M
Q3 25
$649.0M
$1.0B
Q2 25
$635.1M
Q1 25
$613.7M
Q4 24
$647.4M
$966.0M
Q3 24
$660.4M
$1.9B
Q2 24
$645.6M
Net Profit
COLD
COLD
MRNA
MRNA
Q1 26
$-13.7M
Q4 25
$-88.3M
Q3 25
$-11.4M
$-200.0M
Q2 25
$1.5M
Q1 25
$-16.4M
Q4 24
$-36.2M
$-1.1B
Q3 24
$-3.7M
$13.0M
Q2 24
$-64.1M
Gross Margin
COLD
COLD
MRNA
MRNA
Q1 26
Q4 25
31.3%
Q3 25
29.3%
79.6%
Q2 25
30.9%
Q1 25
31.1%
Q4 24
29.7%
23.5%
Q3 24
29.6%
72.4%
Q2 24
31.0%
Operating Margin
COLD
COLD
MRNA
MRNA
Q1 26
2.5%
Q4 25
-10.8%
Q3 25
2.6%
-25.6%
Q2 25
5.9%
Q1 25
3.6%
Q4 24
-1.8%
-129.0%
Q3 24
4.6%
-3.8%
Q2 24
9.8%
Net Margin
COLD
COLD
MRNA
MRNA
Q1 26
-2.4%
Q4 25
-13.7%
Q3 25
-1.8%
-19.7%
Q2 25
0.2%
Q1 25
-2.7%
Q4 24
-5.6%
-115.9%
Q3 24
-0.6%
0.7%
Q2 24
-9.9%
EPS (diluted)
COLD
COLD
MRNA
MRNA
Q1 26
$-0.05
Q4 25
$-0.31
Q3 25
$-0.04
$-0.51
Q2 25
$0.01
Q1 25
$-0.06
Q4 24
$-0.12
$-2.91
Q3 24
$-0.01
$0.03
Q2 24
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COLD
COLD
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$1.1B
Total DebtLower is stronger
Stockholders' EquityBook value
$2.8B
$9.3B
Total Assets
$8.1B
$12.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COLD
COLD
MRNA
MRNA
Q1 26
Q4 25
$136.9M
Q3 25
$33.3M
$1.1B
Q2 25
$101.4M
Q1 25
$38.9M
Q4 24
$47.7M
$1.9B
Q3 24
$61.3M
$1.6B
Q2 24
$44.2M
Stockholders' Equity
COLD
COLD
MRNA
MRNA
Q1 26
$2.8B
Q4 25
$2.9B
Q3 25
$3.0B
$9.3B
Q2 25
$3.1B
Q1 25
$3.2B
Q4 24
$3.3B
$10.9B
Q3 24
$3.4B
$11.9B
Q2 24
$3.4B
Total Assets
COLD
COLD
MRNA
MRNA
Q1 26
$8.1B
Q4 25
$8.1B
Q3 25
$8.1B
$12.1B
Q2 25
$8.1B
Q1 25
$7.8B
Q4 24
$7.7B
$14.1B
Q3 24
$7.9B
$15.8B
Q2 24
$7.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COLD
COLD
MRNA
MRNA
Operating Cash FlowLast quarter
$39.9M
$-847.0M
Free Cash FlowOCF − Capex
$-880.0M
FCF MarginFCF / Revenue
-86.6%
Capex IntensityCapex / Revenue
2.2%
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COLD
COLD
MRNA
MRNA
Q1 26
$39.9M
Q4 25
$130.2M
Q3 25
$78.9M
$-847.0M
Q2 25
$120.3M
Q1 25
$30.2M
Q4 24
$162.6M
$825.0M
Q3 24
$50.6M
$-1.6B
Q2 24
$136.7M
Free Cash Flow
COLD
COLD
MRNA
MRNA
Q1 26
Q4 25
$-12.2M
Q3 25
$-65.4M
$-880.0M
Q2 25
$-57.4M
Q1 25
$-82.3M
Q4 24
$57.4M
$303.0M
Q3 24
$-44.5M
$-1.7B
Q2 24
$73.3M
FCF Margin
COLD
COLD
MRNA
MRNA
Q1 26
Q4 25
-1.9%
Q3 25
-10.1%
-86.6%
Q2 25
-9.0%
Q1 25
-13.4%
Q4 24
8.9%
31.4%
Q3 24
-6.7%
-92.2%
Q2 24
11.4%
Capex Intensity
COLD
COLD
MRNA
MRNA
Q1 26
2.2%
Q4 25
22.1%
Q3 25
22.2%
3.2%
Q2 25
28.0%
Q1 25
18.3%
Q4 24
16.3%
54.0%
Q3 24
14.4%
8.1%
Q2 24
9.8%
Cash Conversion
COLD
COLD
MRNA
MRNA
Q1 26
Q4 25
Q3 25
Q2 25
78.18×
Q1 25
Q4 24
Q3 24
-120.46×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

COLD
COLD

Warehouse services (3)$331.9M57%
Rent and storage$246.1M43%

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons